New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

FUTURE ONCOLOGY
Volume 6 #1/2 December 15, 2000

State-of-the-Art in the Management of Cancer

BLADDER CANCER-PART II

SCREENING, DIAGNOSIS, STAGING, AND FOLLOW-UP

Screening

Diagnosis and Follow-up

  • In vitro Testing Approaches
    • Urine cytology/cytopathology
      • ImmunoCyt
      • Quanticyt
    • Bladder tumor antigen (BTA)
    • Nuclear matrix proteins (NMP)
      • NMP-22
      • BCLA-4
    • Fibrin/fibrinogen degradation products (FDP)
    • Telomerase
    • p53 mutations and other genetic markers
    • Cytokeratin
    • Hyaluronic acid (HA) and hyaluronidase (HAase)
  • Cystoscopy/Biopsy

Histopathology and Bladder Cancer Types

  • Transitional Cell Carcinoma (TCC)
  • Squamous Cell Carcinoma
  • Adenocarcinoma

Stage and Grade

Technology Update

SYNTHETIC NUCLEIC ACID SEQUENCE CONSTRUCTS AS ONCOLOGY THERAPEUTICS - PART II

Types of Synthetic Nucleic Acid Constructs in Development as Oncology Therapeutics

  • Antisense Oligos
  • Triplex-Forming ODN (TFO)
  • Catalytic Nucleic Acids/Ribozymes
    • Hammerhead ribozymes
    • Minizymes
    • Maxizymes
    • Hairpin ribozymes
    • Snorbozymes
    • Deoxyribozymes or DNA enzymes (DNAzymes)
    • Dy-Tex ribozyme analogs
  • Chimeric Nucleotides
  • Intracellularly Produced Antisense RNA and DNA
  • Aptamers
    • Aptazymes
    • Aptamers as diagnostics

Biological Activity of ODN

  • CpG-containing ODN
  • G-rich ODN
  • ODN Conjugated to Radioisotopes

Clinical Considerations

  • Toxicity
  • Administration Route
    • Oral delivery
    • Pulmonary delivery
  • Combination Therapy


HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887